Molecular Diagnostics Center
view more >>
- About MEDx
- Technology Centers
- Services
-
Products
IHC-Based AssaysPCR-Based AssaysNGS-Based AssaysMore AssaysCustomized AssaysSolid Tumor - Pan-Solid Tumors - Lung Cancer - Stomach Cancer - Breast Cancer - Soft Tissue Sarcoma - Other Cancer Types
Solid TumorBlood CancerRUO ProductsIVD/CDx Products - Clinical Testing
- Quality Systems
- Events
- Contact Us
- 400+Pharmaceutical Partners
- 150+Biomarker Assays
- 300+Method Validations
- 40+CDx
Technology Centers
Comprehensive Translational Medicine
Services
CDO Enabling Drug R&D
Products
A Leader of Companion Diagnostics Total-Solution Providers
Clinical Testing
Patient Testing for Precision Medicine
-
Pan solid tumor
Meet the diverse demands from clinicians and patients, MEDx Translational Medicine (MEDx) has developed a series of solid tumor tests, including pan-cancer gene panel tests, single cancer gene panel assays, and immunohistochemistry (IHC). -
Hematologic Malignancy
Most recently, molecular diagnostic products using PCR and next-generation sequencing (NGS) have significantly improved the understanding of molecular mechanism of hematological malignancies, leading to the right choice of molecular targeting drugs for precision therapy for the individual patients in clinic.
Quality Systems
State-of-Art Facilities & Global-standard Quality Systems
About MEDx
Translational Medicine
MEDx Translational Medicine Co., Ltd (simply MEDx) was founded in 2013, formerly known as QIAGEN (Suzhou) Translational Medicine Co., Ltd.Obtained with comprehensive technology platforms, high quality system, and strong IVD R&D experience, MEDx has become a leading innovative company in companion diagnostics and the total solution provider for precision medicine in China.
Taking advantage of the comprehensive translational platforms including genomics, proteomics, cytomics, and pathology, MEDx offers integrated solutions from biomarker discovery, target validation, molecular testing, and patient stratification for drug clinical trials, to the IVD/CDx R&D and commercialization. With a world-class technical team and a rich IVD/CDx pipeline, MEDx collaborates with hundreds of world-renowned pharmaceutical companies.
Events
- MEDx wishes you a happy Christmas！
- MEDx wishes you a happy Thanksgiving！
- Happy Chinese New Year
- MEDx TMC | Happy Mid-Autumn Festival
- MEDx Invite You: Medlab Asia & Asia Health on July 10th-12th, 2024
-
We are honored to invite you to participate in the Medlab Asia & Asia Health, which will take
- MEDx TMC | Happy Father’s Day！
- Dragon Boat Festival
- Welcome to visit the MEDx Booth at Medlab Middle East 2024
-
Time：5-8 February, 2024Address：Dubai World Trade CentreMEDx Booth No: # Z2.H19We are honored
-
19 Aug 2025The Future of Cell and Gene Therapy: Navigating Innovation, Regulation, and Manufacturing Challengesview more >>
19 Aug 2025The Future of Cell and Gene Therapy: Navigating Innovation, Regulation, and Manufacturing Challengesview more >>
-
05 Aug 2025Immunotherapy-Related Diabetes Linked to New Immune Cell Targeted by JAK Inhibitors in Mouse Modelview more >>
05 Aug 2025Immunotherapy-Related Diabetes Linked to New Immune Cell Targeted by JAK Inhibitors in Mouse Modelview more >>
- The Future of Cell and Gene Therapy: Navigating Innovation, Regulation, and Manufacturing Challenges
-
An interview with Philip Vanek, chief commercialization officer of the International Society for Cel
- Immunotherapy-Related Diabetes Linked to New Immune Cell Targeted by JAK Inhibitors in Mouse Model
-
A team of researchers at UCLA Health Jonsson Comprehensive Cancer Center has identified a potential
- Confined Cancer Cells Undergo Nuclear ATP Surge, Unlocks Therapy Target
-
Cancer cells undergo physically constraining processes, such as intravasation, extravasation, and ti
- Instil's licensed PD-L1xVEGF bispecific shows promise in China, instilling hope for upcoming US test
-
A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise
- Fighting leukemia by breaking a hidden cell loop
-
Researchers at MUSC Hollings Cancer Center have identified a signaling loop involved in the growth a
- Modified personalized cancer vaccine generates powerful immune response
-
Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanom
- Aggressive breast cancer triggered by obesity-related blood signals, study shows
-
Breast cancer is the most commonly diagnosed cancer among women worldwide and represents a major pub
- Amgen’s Antibody Improves Overall Survival in Phase III Gastric Cancer Test
-
A combination of Amgen’s monoclonal antibody bemarituzumab and chemotherapy improved overall surviv
Follow MEDx
